Država: Armenija
Jezik: engleski
Izvor: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
human rotavirus vaccine live
GlaxoSmithKline Biologicals s.a.
J07BH01
human rotavirus vaccine live
not less than 10^6CCID^50/dose
suspension oral
(50) plastic tube 1.5ml (1 dose)
Prescription
Registered
2017-07-10
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Rotarix ORAL suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Human rotavirus RIX4414 strain (live, attenuated)* not less than 10 6.0 CCID 50 *Produced on Vero cells Excipient with known effect: This product contains sucrose 1,073 mg (see section 4.4). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM ORAL suspension. Rotarix is a clear and colourless liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Rotarix is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastro- enteritis due to rotavirus infection (see sections 4.2, 4.4 and 5.1). The use of Rotarix should be based on official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix may be given with the same posology to preterm infants born after at least 27 weeks of gestational age (see sections 4.8 and 5.1). In clinical trials, spitting or regurgitation of the vaccine has rarely been observed and, under such circumstances, a replacement dose was not given. However, in the unlikely event that an infant spits out or regurgitates most of the vaccine dose, a single replacement dose may be given at the same vaccination visit. It is recommended that infants who receive a first dose of Rotarix complete the 2-dose regimen with Rotarix. There are no data on safety, immunogenicity or efficacy when Rotarix is administered for the first dose and another rotavirus vaccine is administered for the second dose or vice versa. _Paediatric population _ Rotarix should not be used in children over 24 weeks of age. Method of administration Rotarix is for ORAL use only. ROTARIX Pročitajte cijeli dokument